|
1
|
Mangas A, Coveñas R, Bodet D, Duleu S and
Geffard M: A new drug candidate (GEMSP) for multiple sclerosis.
Curr Med Chem. 16:3203–3214. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sawcer S, Hellenthal G, Pirinen M, Spencer
CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt
SE, et al: International Multiple Sclerosis Genetics Consortium;
Wellcome Trust Case Control Consortium 2: Genetic risk and a
primary role for cell-mediated immune mechanisms in multiple
sclerosis. Nature. 476:214–219. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kutzelnigg A, Lucchinetti CF, Stadelmann
C, Brück W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE and
Lassmann H: Cortical demyelination and diffuse white matter injury
in multiple sclerosis. Brain. 128:2705–2712. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Villar LM, Sádaba MC, Roldán E, Masjuan J,
González-Porqué P, Villarrubia N, Espiño M, García-Trujillo JA,
Bootello A and Alvarez-Cermeño JC: Intrathecal synthesis of
oligoclonal IgM against myelin lipids predicts an aggressive
disease course in MS. J Clin Invest. 115:187–194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mangas A, Coveñas R and Geffard M: New
drug therapies for multiple sclerosis. Curr Opin Neurol.
23:287–292. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Geffard M, de Bisschop L, Duleu S, Pouns
O, Ferran G, Bassede A, Hassaine N, Autran JL, Bodet D, Mangas A
and Coveñas R: Endotherapia. Antiinflamm Antiallergy Agents Med
Chem. 9:197–211. 2010. View Article : Google Scholar
|
|
7
|
Geffard M, Duleu S, Bessede A, Vigier V,
Bodet D, Mangas A and Coveñas R: GEMSP: A new therapeutic approach
to multiple sclerosis. Cent Nerv Syst Agents Med Chem. 12:173–181.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shih IL, Van YT and Shen MH: Biomedical
applications of chemically and microbiologically synthesized
poly(glutamic acid) and poly(lysine). Mini Rev Med Chem. 4:179–188.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Geffard M, de Bisschop L, Duleu S,
Hassaine N, Mangas A and Coveñas R: Endotherapia: A new frontier in
the treatment of multiple sclerosis and other chronic diseases.
Discov Med. 10:443–451. 2010.PubMed/NCBI
|
|
10
|
Mangas A, Coveñas R, Bodet D, Dabadie MP,
Glaize G and Geffard M: Evaluation of the effects of a new drug on
brain leukocyte infiltration in an experimental model of autoimmune
encephalomyelitis. Lett Drug Des Discov. 3:138–148. 2006.
View Article : Google Scholar
|
|
11
|
Mangas A, Coveñas R, Bodet D, de León M,
Duleu S and Geffard M: Evaluation of the effects of a new drug
candidate (GEMSP) in a chronic EAE model. Int J Biol Sci.
4:150–160. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Villoslada P: Neuroprotective therapies
for multiple sclerosis and other demyelinating diseases Mult Scler
Demyel Dis. 1:12016. View Article : Google Scholar
|
|
13
|
Mangas A, Coveñas R, Bodet D and Geffard
M: Antisera and immunocytochemical techniquesBrain molecules: From
vitamins to molecules for axonal guidance. Mangas A, Coveñas R and
Geffard M: Transworld Research Network; Trivandrum: pp. 1–25.
2008
|
|
14
|
Mangas A, Vecino E, Rodríguez F David,
Geffard M and Coveñas R: GEMSP exerts a myelin-protecting role in
the rat optic nerve. Neurol Res. 35:903–911. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Noseworthy JH, Lucchinetti C, Rodríguez M
and Weinshenker BG: Multiple sclerosis. N Engl J Med. 343:938–952.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
van Meeteren ME, Teunissen CE, Dijkstra CD
and van Tol EA: Antioxidants and polyunsaturated fatty acids in
multiple sclerosis. Eur J Clin Nutr. 59:1347–1361. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Agar J and Durham H: Relevance of
oxidative injury in the pathogenesis of motor neuron diseases.
Amyotroph Lateral Scler Other Motor Neuron Disord. 4:232–242. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Crouzin N, de Jesus Ferreira MC,
Cohen-Solal C, Aimar RF, Vignes M and Guiramand J:
Alpha-tocopherol-mediated long-lasting protection against oxidative
damage involves an attenuation of calcium entry through TRP-like
channels in cultured hippocampal neurons. Free Radic Biol Med.
42:1326–1337. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Blondeau N, Widmann C, Lazdunski M and
Heurteaux C: Polyunsaturated fatty acids induce ischemic and
epileptic tolerance. Neuroscience. 109:231–241. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yoshida H, Yanai H, Namiki Y,
Fukatsu-Sasaki K, Furutani N and Tada N: Neuroprotective effects of
edaravone: A novel free radical scavenger in cerebrovascular
injury. CNS Drug Rev. 12:9–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Di Biase A and Salvati S: Exogenous lipids
in myelination and myelination. Kaohsiung J Med Sci. 13:19–29.
1997.PubMed/NCBI
|
|
22
|
Medina JM and Tabernero A:
Astrocyte-synthesized oleic acid behaves as a neurotrophic factor
for neurons. J Physiol Paris. 96:265–271. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ebringer A, Hughes L, Rashid T and Wilson
C: Acinetobacter immune responses in multiple sclerosis:
Etiopathogenetic role and its possible use as a diagnostic marker.
Arch Neurol. 62:33–36. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hughes LE, Bonell S, Natt RS, Wilson C,
Tiwana H, Ebringer A, Cunningham P, Chamoun V, Thompson EJ, Croker
J, et al: Antibody responses to Acinetobacter spp. and Pseudomonas
aeruginosa in multiple sclerosis: Prospects for diagnosis using the
myelin-acinetobacter-neurofilament antibody index. Clin Diagn Lab
Immunol. 8:1181–1188. 2001.PubMed/NCBI
|
|
25
|
Furrows SJ, Hartley JC, Bell J, Silver N,
Losseff N, Stevenson S, Chapman M, Thompson EJ, Ridgway GL and
Giovannoni G: Chlamydophila pneumoniae infection of the central
nervous system in patients with multiple sclerosis. J Neurol
Neurosurg Psychiatry. 75:152–154. 2004.PubMed/NCBI
|
|
26
|
Victor VM and De La Fuente M: Changes in
the superoxide production and other macrophage functions could be
related to the mortality of mice with endotoxin-induced oxidative
stress. Physiol Res. 52:101–110. 2003.PubMed/NCBI
|
|
27
|
Bohatschek M, Werner A and Raivich G:
Systemic LPS injection leads to granulocyte influx into normal and
injured brain: Effects of ICAM-1 deficiency. Exp Neurol.
172:137–152. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lehnardt S, Lachance C, Patrizi S,
Lefebvre S, Follett PL, Jensen FE, Rosenberg PA, Volpe JJ and
Vartanian T: The toll-like receptor TLR4 is necessary for
lipopolysaccharide-induced oligodendrocyte injury in the CNS. J
Neurosci. 22:2478–2486. 2002.PubMed/NCBI
|
|
29
|
Johnson KP, Brooks BR, Cohen JA, Ford CC,
Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB,
et al: Extended use of glatiramer acetate (Copaxone) is well
tolerated and maintains its clinical effect on multiple sclerosis
relapse rate and degree of disability. Copolymer 1 Multiple
Sclerosis Study Group. Neurology. 50:701–708. 1998. View Article : Google Scholar : PubMed/NCBI
|
